THE DRAMATIC EMERGENCE OF BIOPHARMACEUTICS as one of the sciences with significant clinical importance is one of the most important developments in patient care today. Research by numerous scientists in many countries during the past several years has demonstrated the direct relationship between proper formulation of a drug and the production of a clinically effective drug product.
Biopharmaceutics is the study of the influence of formulation on the therapeutic activity of a drug product. Research scientists have examined the factors that influence the absorption of the dru~, its distribution in the body tissues, its metabolism, its rate of excretion, and its interactions with other drugs. Relationships have been established between formulation and ther11peutic activity in regard to such factors as particle size, dissolution and disintegration rates, the rate of release of medicaments from different vehicles, the presence or absence of surface active agents, the presence or absence of other ions which either enhance or depress absorption, the vehicles in which the drug is formulated, the molecular wei~t (for example, of dextran and its biological activity), and many others.
In this issue ·of DRUG INTEI.LIGENCE, beginning on page 66, we are publishing the first in a series of annotated references on this important subject so that our readers may review for themselves some of the research findings in this field.
The therapeutic activity of a drug is ultimately due to its ability to modify biological processes at the cellular level. The patient's response to a drug is determined by the amount of free or unbound drug present in the plasma and by its ability to combine with specific receptors at their site in various organs and tissues. The therapeutic activity or the biological effects of a drug can be destroyed by poor formulation. Thus all the time and effort spent in the patient's hospitalization, laboratory tests, and medical diagnosis are wasted unless he is given a clinically effective product with which to treat his illness. These facts do not seem to be appreciated by those who advocate the use of drugs from any source of supply.
It is true that many hospitals purchase drugs under their non-proprietary or "generic" names, but it is equally true that they determine and control their acceptable sources of supply. It is true that the President of the United States, senators, representatives, and other government officials are given "generic" drugs (many are trade named products) when they go to the Naval Medi-Drug lntelligence VOL 1 FEB 67 cal Center, to Walter Reed Hospital, or to some other government hospital; but it is also true that the producers of these drugs and the drugs themselves undergo the most rigorous examination and inspection by the Department of Defense.
These inspections are carried out by a team at the Medical Directorate, Defense Personnel Support Center in Philadelphia. Approximately 50 percent of pharmaceutical ~rms inspected do not qualify as suppliers to the Department of Defense because of poor manufacturing practices, inadequate control procedures, poor sanitation, or for some other reason. In turn, the products of more than half of those qualifying as suppliers are rejected because of deficiencies. Thus, to apply the principle that because the President is given "generic" drugs they may be given with equal safety to the civilian population is to lose sight of the most important factor: the inspection and control of all sources of supply and the analysis of all drug products.
The question is really not a matter of "generic" drugs versus trade named drugs, and it never ·has been. It is one of the quality of the drug products and the reputation and facilities of the pharmaceutical manufacturer to produce them. Many so called "generic" drug products are sold by the top ten pharmaceutical companies. These products are sold under their nonproprietary or "generic" names. Many trade named drug products are sold by little-known companies.
Trade or "generic" names do not make a drug; a manufacturer does, and how he makes it and controls it, not what he names it, is important. It is unfortunate that some spokesmen for the drug industry use the term "generic" drug to imply drugs of inferior or questionable quality purchased from unreliable manufacturers because these same manufacturers produce trade named drugs also. This distorts the basic question which is that of a drug's quality and not its name.
The preparation of dosage forms of today's drugs is a sophisticated science requiring skilled, highly trained personnel working with complicated machinery and complex analytical apparatus. Let us not confuse the quality of drugs with the names they bear, and let's not assume that all "generic" drugs are equivalent because, obviously, there is a great difference among drug products. It would be a tragedy if all the research in biopharmaceutics were ignored and drugs from any source were approved for use by patients.
